A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
It’s only 2012, but Russia’s Pharma 2020 program hit new highs last month with novel deals from Abbott, J&J, Merck and Pfizer.
You may also be interested in...
Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.
Merck Makes Hepatitis C A Priority
Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.
Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build
WASHINGTON - In the latest announcement from Big Pharma about going local in Russia, Pfizer Inc. said June 29 that it had signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries